Absolute CT perfusion parameter values after the neoadjuvant chemoradiotherapy of the squamous cell esophageal carcinoma correlate with the histopathologic tumor regression grade

被引:27
|
作者
Djuric-Stefanovic, A. [1 ,2 ]
Micev, M. [1 ,3 ]
Stojanovic-Rundic, S. [1 ,4 ]
Pesko, P. [1 ,5 ]
Saranovic, Dj [1 ,2 ]
机构
[1] Univ Belgrade, Fac Med, Belgrade 11001, Serbia
[2] Clin Ctr Serbia, Ctr Radiol & MR, Surg Univ Clin 1, Dept Digest Radiol, Belgrade, Serbia
[3] Clin Ctr Serbia, Surg Univ Clin 1, Dept Pathol, Belgrade, Serbia
[4] Inst Oncol & Radiol Serbia, Dept Radiat Oncol, Clin Radiat Oncol & Diagnost, Belgrade, Serbia
[5] Clin Ctr Serbia, Surg Univ Clin 1, Belgrade, Serbia
关键词
CT perfusion; Esophageal carcinoma; Neoadjuvant chemoradiotherapy; Response evaluation; Tumor regression grade; COMPUTED-TOMOGRAPHY; CANCER; THERAPY; PET; MANAGEMENT; SURVIVAL; UTILITY;
D O I
10.1016/j.ejrad.2015.09.025
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To analyze value of the computed tomography (CT) perfusion imaging in response evaluation of the esophageal carcinoma to neoadjuvant chemoradiotherapy (nCRT) using the histopathology as reference standard. Methods: Forty patients with the squamous cell esophageal carcinoma were re-evaluated after the nCRT by CT examination, which included low-dose CT perfusion study that was analyzed using the deconvolution-based CT perfusion software (Perfusion 3.0, GE). Histopathologic assessment of tumor regression grade (TRG) according to Mandard's criteria served as reference standard of response evaluation. Statistical analysis was performed using Spearman's rank correlation coefficient (rs) and Kruskal-Wallis's test. Results: The perfusion CT parameter values, measured after the nCRT in the segment of the esophagus that had been affected by neoplasm prior to therapy, significantly correlated with the TRG: blood flow (BF) (rs = 0.851; p <0.001), blood volume (BV) (rs = 0.732; p <0.001) and mean transit time (MU) (rs = 0.386; p = 0.014). Median values of BF and BV significantly differed among TRG 1-4 groups (p < 0.001), while maximal esophageal wall thickness did not (p = 0.102). Median BF and BV were gradually rose and MU decreased as TRG increased, from 21.4 ml/min/100 g (BF), 1.6 ml/100 g (BV) and 8.6s (MU) in TRG 1 group, to 37.3 ml/min/100 g, 3.5 ml/100 g and 7.5 s in TRG 2 group, 81.4 ml/min/100 g, 4.1 ml/100 g and 3.8 s in TRG 3 group, and 121.1 ml/min/100 g, 4.9 ml/100 g and 3.7 s in TRG 4 group. In all 15 patients who achieved complete histopathologic regression (TRG 1), BF was <30.0 ml/min/100 g. Conclusions: CT perfusion could improve the accuracy in response evaluation of the esophageal carcinoma to nCRT. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:2477 / 2484
页数:8
相关论文
共 50 条
  • [31] Circulating tumor DNA (ctDNA) in predicting residual disease after neoadjuvant chemoradiotherapy (nCRT) for esophageal squamous cell carcinoma (ESCC).
    Liu, Zhichao
    Yang, Yang
    Liu, Jun
    Zhu, Li
    Yu, Hong
    Zhu, Mingjun
    Yang, Xi Li Jie
    Xiang, Jianxing
    Li, Haiyan
    Li, Bing
    Li, Zhigang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] Prognostic significance of positive lymph node regression grade to neoadjuvant chemoradiation for esophageal squamous cell carcinoma
    Zhou, Yehan
    Liu, Ying
    Guo, Peng
    Huang, Zongyao
    Zhou, Chengmin
    Yang, Hong
    Qin, Sheng
    Zhu, Jie
    Wang, Yi
    Leng, Xuefeng
    He, Wenwu
    Wang, Qifeng
    Liu, Yang
    JOURNAL OF SURGICAL ONCOLOGY, 2024, 129 (04) : 708 - 717
  • [33] ASO Author Reflections: Exploring the Best Parameter for Lymph Node Assessment in Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy
    Huang, Xu
    Tan, Lijie
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (02) : 1292 - 1293
  • [34] ASO Author Reflections: Exploring the Best Parameter for Lymph Node Assessment in Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy
    Xu Huang
    Lijie Tan
    Annals of Surgical Oncology, 2024, 31 : 899 - 900
  • [35] Genomic characteristics in neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma
    He, Wenwu
    Leng, Xuefeng
    Wang, Kangning
    Mao, Tiaoqin
    Peng, Lin
    Fang, Qiang
    Xiao, Wenguang
    Han, Yongtao
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2020, 11 (06) : 1105 - 1112
  • [36] Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma
    Ren-Wen Huang
    Yin-Kai Chao
    Yu-Wen Wen
    Hsien-Kun Chang
    Chen-Kan Tseng
    Sheng-Chieh Chan
    Yun-Hen Liu
    World Journal of Surgical Oncology, 12
  • [37] Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma
    Huang, Ren-Wen
    Chao, Yin-Kai
    Wen, Yu-Wen
    Chang, Hsien-Kun
    Tseng, Chen-Kan
    Chan, Sheng-Chieh
    Liu, Yun-Hen
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2014, 12
  • [38] Esophageal squamous cell carcinoma treated by definitive or neoadjuvant chemoradiotherapy with or without paclitaxel
    Hsu, F. M.
    Cheng, J. C.
    Lin, C. C.
    Lee, Y. C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S278 - S278
  • [39] Neoadjuvant chemoradiotherapy with camrelizumab in patients with locally advanced esophageal squamous cell carcinoma
    Chen, Fei
    Qiu, Lingdong
    Mu, Yushu
    Sun, Shibin
    Yuan, Yulong
    Shang, Pan
    Ji, Bo
    Wang, Qifei
    FRONTIERS IN SURGERY, 2022, 9
  • [40] The Role of Adjuvant Chemotherapy after Neoadjuvant Chemoradiotherapy Followed by Surgery in Patients with Esophageal Squamous Cell Carcinoma
    Park, Seong Yong
    Kim, Hong Kwan
    Jeon, Yeong Jeong
    Lee, Junghee
    Cho, Jong Ho
    Choi, Yong Soo
    Shim, Young Mog
    II Zo, Jae
    CANCER RESEARCH AND TREATMENT, 2023, 55 (04): : 1231 - 1239